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TO THE EDITOR
Familial chilblain lupus is a rare auto-
somal dominant form of lupus erythe-
matosus with cold-induced bluish red
inflammatory infiltrates of acral skin that
may ulcerate (Lee-Kirsch et al., 2006). In
contrast to sporadic chilblain lupus that
occurs mainly in adolescent and adult
patients, familial chilblain lupus mani-
fests in early childhood and is caused by
heterozygous mutations of genes encod-
ing TREX1 (3’ repair exonuclease) or
the phosphohydrolase SAMHD1 (sterile
alpha motif domain and HD domain
containing protein 1) (Rice et al., 2007;
Lee-Kirsch et al., 2007a; Gunther et al.,
2009; Ravenscroft et al., 2011). TREX1
represents the major intracellular 3’-5’
DNA exonuclease and has a high
specificity for single-stranded DNA
particularly for single-stranded 3’ over-
hangs of double-stranded DNA (Mazur
and Perrino, 2001). SAMHD1 degrades
deoxynucleotides, the building blocks
of DNA synthesis and has also 3’-5’
exonuclease activity (Lee-Kirsch et al.,
2013).
TREX1 deficiency was shown to cause
intracellular accumulation of single-
stranded DNA which may originate
from DNA repair processes or the life
cycle of endogenous retroelements
(Yang et al., 2007; Stetson et al., 2008).
It is thought that recognition of these
inappropriately accumulated nucleic
acids by the innate immune system
leads to a type I IFN response that subse-
quently induces autoimmunity. TREX1-
deficient mice succumb to circulatory
failure due to autoimmune-mediated
inflammation of the heart and other
organs (Morita et al., 2004; Gall et al.,
2012). Genetic ablation of type I IFN
signaling in TREX1-deficient mice can
fully rescue this phenotype proving a
pivotal role of type I IFN activation
in the development of autoimmunity
(Morita et al., 2004; Stetson et al., 2008).
Type I IFN upregulation is also a
typical feature of the rare inflammatory
encephalopathy Aicardi–Goutie`res syn-
drome (AGS) that clinically resembles
intrauterine viral infection (Aicardi
and Goutieres, 1984). AGS phenotypi-
cally and genetically overlaps with
systemic lupus erythematosus (SLE),
and like SLE is also characterized by
chronic activation of the type I IFN
system (Ramantani et al., 2010). AGS
is an autosomal recessive disorder
caused by biallelic mutations in
TREX1, SAMHD1, the three subunits of
the RNase H2 complex and adenosin
deaminase acting on RNA1 (Lee-Kirsch
et al., 2013). Since all AGS-causing
genes encode enzymes which act on
nucleic acid substrates, these findings
suggests that defects in nucleic acid
metabolism can trigger autoimmunity.
Given the role of type I IFN in the
pathogenesis of SLE and AGS (Wenzel
et al., 2005; Lee-Kirsch et al., 2013), we
investigated type I IFN responses in
patients with familial chilblain lupus.
We analyzed skin and blood of five
patients with familial chilblain lupus
carrying a heterozygous D18N muta-
tion in TREX1 for expression of type I
IFN-induced genes and proteins. In
cutaneous lesions from patients with
familial chilblain lupus, we detected
high expression of the type I IFN indu-
cible myxovirus resistance protein A
and CXCL10 (Figure 1a) indicating an
ongoing type I IFN response. Interest-
ingly, weak expression of myxovirus
resistance protein A was also detectable
in non-lesional skin of patients with
familial chilblain lupus consistent with
a chronic weak type I IFN activation
(Figure 1a).
Unlike sera from patients with spora-
dic chilblain lupus or healthy controls,
sera of patients with TREX1-associated
familial chilblain lupus contained ele-
vated concentrations of the type I
IFN inducible chemokine CXCL10
(Figure 1b). We next examined mRNA
levels of three type I IFN-induced genes
in peripheral blood cells and found them
increased in patients with familial com-
pared with sporadic chilblain lupus and
healthy controls (Figure 1c).
Impairment of the nucleic acid meta-
bolism in patients with TREX1-asso-
ciated chilblain lupus is present from
birth, consistent with the onset of clin-
ical manifestations within the first years
of life, which is in contrast to the later
manifestation of disease observed in
sporadic chilblain lupus. The higher
expression of type I IFN-induced genes
and CXCL10 in sera of patients with
familial compared with polygenic spora-
dic chilblain lupus may reflect a more
sustained chronic activation of the type I
IFN system and a more vigorous auto-
immune response caused by TREX1
deficiency. Indeed, clinical investigation
of patients revealed a more severe phe-
notype in patients with familial com-
pared with sporadic chilblain lupus. The
cutaneous involvement scored by CLASI
(cutaneous lupus activity and severity
index) or RCLASI (revised CLASI) of
patients with TREX1-associated chilblain
lupus was more severe compared with
sporadic chilblain lupus (Figure 1d) and
the patients with TREX1 mutations
showed an increased prevalence of sys-
temic involvement including hematolo-
gic abnormalities, polyarthritis and
antinuclear antibodies (Supplementary
Table S1 online).
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These observations are in keeping
with the finding that heterozygous muta-
tions in TREX1 confer an increased risk
for SLE (Lee-Kirsch et al., 2007b). There-
fore, clinicians should be aware of
systemic manifestations of lupus erythe-
matosus in patients with familial chilb-
lain lupus. Furthermore, our findings
also suggest a common pathogenesis of
TREX1-associated cutaneous lupus erythe-
matosus and TREX1-associated SLE.
To further investigate this hypothesis,
we examined TREX1-deficient mice
(Morita et al., 2004), which develop
type I IFN-dependent systemic auto-
immune disease, for signs of cutaneous
inflammation. Macroscopic inspection
of 3–8–weeks-old homozygous TREX1-
deficient mice revealed variable ery-
thema or erythematous infiltrates with
fine scaling in up to 50% of cases
(Figure 2a and b). These lesions were
not detected in wild-type littermate con-
trols but also occurred in one of nine
heterozygous mice. Differences in pene-
trance and expressivity or the necessity
of additional disease-promoting genetic
or environmental factors might explain
the lower rate of cutaneous involvement
in heterozygous mice compared with
patients with dominant familial chilblain
lupus. The coat of TREX1-deficient ani-
mals appeared less glossy and dense. In
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Figure 1. Upregulation of type I IFN-induced transcripts and proteins in skin and blood of patients with familial chilblain lupus. (a) Expression of CXCL10 and
myxovirus resistance protein A in lesional skin (one representative of three biopsies stained is shown) and non-lesional skin of patients with TREX1-associated
familial chilblain lupus. Bar¼100mm. (b) Serum levels of the type I IFN-induced chemokines CXCL10 and CXCL9 in patients with TREX1-associated
familial chilblain lupus (TREX1 ChLE, n¼4), with sporadic chilblain lupus (spor. ChLE; n¼8) and healthy control sera (HD; n¼ 17). Box plots show the
interquartile range (box), median (line), and SD (whisker) (*Po0.05; **Po0.01; Kruskal–Wallis test and post hoc Wilcoxon test with Bonferroni correction).
(c) Expression of type I IFN inducible genes IFIT1, IFI44, and CXCL10 in peripheral blood cells from patients with TREX1-associated familial chilblain lupus
(TREX1 ChLE; n¼5), sporadic chilblain lupus (spor. ChLE; n¼ 6), and healthy controls (HD; n¼6) determined by quantitative real time RT-PCR. mRNA levels
were normalized to hypoxanthine phosphoribosyltransferase mRNA. Shown are the means±SD. (*Po0.05; **Po0.01, one-way analysis of variance
(ANOVA) and post hoc Tukey’s (HSD) test). Expression of IFIT1 was significantly higher in spor. ChLE compared with healthy controls (P¼0.005) (d) Comparison
of the cutaneous lupus activity and severity score (CLASI, Albrecht J, J Invest Dermatol 05) and the revised CLASI (RCLASI, Kuhn A, Br J Dermatol 10) of 5 patients
with familial TREX1-associated chilblain lupus (TREX1 ChLE) versus 10 patients with sporadic chilblain lupus (spor. ChLE). Patients with TREX1 ChLE were
significantly more severely affected in terms of activity (a, open boxes) and damage (d, filled boxes) compared with spor. ChLE (**Po0.01; ***Po0.001;
Mann–Whitney U test). Box plots show the interquartile range (box), median (line) and SD (whisker).
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addition, two animals developed loca-
lized diffuse alopecia, which was not
observed in controls. Histologically skin
lesions showed marked acanthosis,
hyperkeratosis, increased leukocyte
infiltration of the dermis and localized
vacuolar degeneration of the basal cell
layer (Figure 2c). Less pronounced but
similar histological changes were also
frequently detected in non-lesional skin
of TREX1- deficient mice. The dermal
cellular infiltrate contained increased
numbers of MHC class II positive anti-
gen presenting cells, whereas CD3þ
lymphocytes were mainly located in
the epidermis and only marginally
increased in TREX1-deficient mice
(Figure 2d, Supplementary Figure S1
online). Along the basement mem-
brane zone, immunofluorescence stain-
ing revealed enhanced deposition of
immune complexes (IgG and IgM) and
complement C3 in mutant versus wild-
type littermate controls (Supplementary
Figure S1 online), a feature consistent
with immune activation in these animals.
Skin of TREX1-deficient mice showed
enhanced expression of the type I IFN-
induced genes Ifit1, Ifi44 and Cxcl10
suggestive of type I IFN mediated induc-
tion (Figure 2e). The cellular source of
type I IFN within cutaneous lesions could
be either non-hematopoietic or hemato-
poietic cells. Gall et al. suggested non-
hematopoietic cells as an important
source of the pathogenic type I IFN in
TREX1-deficient heart (Gall et al., 2012).
As TREX1 is ubiquitously expressed, this
would be in support of a cell-intrinsic
origin of type I IFN activation. In addition,
external triggers including cold may
modulate the local immune response.
Taken together, the finding of sponta-
neous type I IFN-dependent cutaneous
pathology in TREX1-deficient mice illus-
trates common pathogenetic pathways in
cutaneous as well as systemic TREX1-
associated lupus erythematosus.
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Figure 2. Spontaneous cutaneous lesions in TREX1-deficient mice. (a) Development of spontaneous skin lesions in Trex1 / mice. WT: wild type (n¼9); þ / :
heterozygous (n¼ 9);  / : homozygous (n¼ 19). (b) Skin of TREX1-deficient mice showing cutaneous erythematous lesions with fine scaling. (c) Hematoxylin
eosin (HE) staining of paraffin-embedded sections of TREX1-deficient mice showing acanthosis, hyperkeratosis, increased cellular infiltration of the dermis, and
localized vacuolar degeneration of the basal cell layer. Magnification 400 ; scale bar¼30mm (d) Quantitative analysis of MHC class II and CD3þ cells in
normal skin from WT mice (open bar, n¼ 10), skin from heterozygous (gray bar, n¼ 8) or homozygous TREX1-deficient (black bar, n¼ 9) mice. Shown are
means±SD. (*Po0.05; one-way analysis of variance (ANOVA) and post hoc Tukey’s (HSD) test) (e) Expression of the type I IFN-induced genes Ifit1, Ifi44, Ifi27,
Cxcl10 in skin determined by quantitative real time RT-PCR and normalized to Tbp gene. WT: wild type (n¼ 6); þ / : heterozygous (n¼ 5);  / : homozygous
(n¼ 7). Shown are means±and SEM. Differences were analyzed by one-way ANOVA and post hoc Tukey’s (HSD) test (*Po0.05).
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Polymorphisms in IL-1B Distinguish between Psoriasis of
Early and Late Onset
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TO THE EDITOR
Chronic plaque psoriasis is a common,
genetic, immune-mediated skin disor-
der that can be dichotomized according
to age of onset: early-onset psoriasis
(EOP; type 1, onset before 40 years of
age, B75% of subjects) and late-onset
psoriasis (LOP; type 2, onset over 40
years of age, B25% of subjects;
Henseler and Christophers, 1985).
Recently, genome-wide association
studies (GWAS) have made significant
strides in elucidating the genetic basis
of EOP with a total of 36 loci now
identified (He´bert et al., 2012; Tsoi
et al., 2012). In comparison, there are
only two genetic studies speci-
fically in LOP: one found no
association with HLA-Cw6, the major
genetic locus associated with EOP
(Allen et al., 2004; Gudjonsson et al.,
2006) while a second separate study
found a nominal association with a
variant (rs16944) mapping to the IL1B
promoter region (Reich et al., 2002).
Inflammatory cytokines, such as IL-1-
beta (IL1b) and tumor necrosis factor-
alpha (TNF-a), have a well-documented
role in the pathogenesis of psoriasis
(Griffiths and Barker, 2007; Nestle
et al., 2009). They are important
stimuli of the migration of epidermal
Langerhans cells (LC) and plasmacytoid
dendritic cells from the skin to draining
lymph nodes where they engage with T
cells. It has been shown that LC
migration in response to these cyto-
kines differs between EOP and LOP
(Cumberbatch et al., 2006; Shaw et al.,
2010). This combination of genetic and
immunological observations implicating
a role for IL1b in mechanisms under-
lying LOP led us to investigate
whether genetic variation at the IL1B
gene is associated with psoriasis. We
compared association of polymorphisms
from IL1B between cohorts of EOP and
LOP patients.
Patients of Caucasian descent with
chronic plaque psoriasis were recruited
from UK Dermatology Centres at Salford
Royal NHS Foundation Trust, Manche-
ster, UK; Guy’s Hospital, London and
the National Hospital for Rheumatic
Diseases, Bath, UK. The study adheres
to the Declaration of Helsinki Princi-
ples, was approved by the relevant local
research ethics committees, and all
subjects provided written informed
consent.Accepted article preview online 20 September 2013; published online 12 December 2013
Abbreviations: CI, confidence interval; EOP, early-onset psoriasis; IL1b, IL-1-beta; LC, Langerhans cell;
LOP, late-onset psoriasis; OR, odds ratio; SNP, single-nucleotide polymorphism; TNF-a, tumor necrosis
factor-alpha
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